RAC1 and head and neck cancer: These findings provide evidence supportive of the precision drugging of RAC1-amp or RAC1-A159V-mutated head and neck cancer patients (~5% cases of HNSCC, based on the Cancer Genome Atlas (TCGA) data) with new Rac1 inhibitors in clinical settings.